Hospital
Ihc Health Services, INC.
Ihc Health Services, INC. was paid $68.77M by Medicaid between Jan 2018 and Nov 2024, across 338 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 67% of everything it billed.
33Billing provider infoIHC HEALTH SERVICES, INC.
MURRAY, UT 84107
MURRAY, UT 84107
33aNPI1043220650assigned 08/08/2006
33bProvider typeRehabilitation Hospital Unit
28Total paid$68.77M
24GClaims1,094,186
24DCodes billed338
24AFirst – last monthJan 2018 – Nov 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SMITH, DENIS controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 168,974 | $9.39M | |
| 2019 | 190,119 | $10.75M | |
| 2020 | 209,761 | $13.43M | |
| 2021 | 265,992 | $17.88M | |
| 2022 | 235,403 | $16.24M | |
| 2023 | 19,026 | $892K | |
| 2024incomplete | 4,911 | $198K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 67% | 99,802 | 49,217 | $46.21M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.5% | 65,176 | 51,969 | $2.37M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 31,797 | 26,387 | $1.44M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.7% | 29,045 | 25,865 | $1.14M |
| A0431 | Ambulance service, conventional air services, transport, one way (rotary wing) | 1.4% | 1,612 | 1,370 | $977K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 6,042 | 5,093 | $894K |
| 78431 | 1.2% | 1,136 | 1,018 | $805K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.2% | 5,302 | 2,271 | $802K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.0% | 7,093 | 6,514 | $709K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | <1% | 40,225 | 34,510 | $661K |
| A0430 | Ambulance service, conventional air services, transport, one way (fixed wing) | <1% | 453 | 381 | $656K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,815 | 4,275 | $639K |
326 more codes
| 80050 | General health panel | <1% | 5,882 | $460K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 814 | $454K |
| 99285 | Emergency room visit (most serious) | <1% | 25,528 | $393K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,247 | $392K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 12,288 | $299K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 6,194 | $283K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,987 | $264K |
| A0435 | Fixed wing air mileage, per statute mile | <1% | 460 | $243K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,662 | $239K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 21,832 | $227K |
| 0482T | <1% | 783 | $222K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 1,251 | $221K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,102 | $221K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 15,993 | $201K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,694 | $190K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,855 | $183K |
| 85610 | <1% | 14,956 | $167K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,031 | $163K |
| 80047 | <1% | 2,926 | $161K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,027 | $159K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,888 | $157K |
| C1769 | Guide wire | <1% | 2,145 | $153K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,791 | $150K |
| 85027 | <1% | 5,751 | $150K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,008 | $148K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,805 | $144K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 24,082 | $140K |
| J2704 | Injection, propofol, 10 mg | <1% | 11,416 | $139K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,236 | $126K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 17,646 | $125K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,227 | $121K |
| 77066 | Tomosynthesis, mammo | <1% | 1,210 | $116K |
| 81001 | <1% | 29,767 | $115K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,668 | $114K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,295 | $112K |
| A0436 | Rotary wing air mileage, per statute mile | <1% | 1,626 | $110K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 27,571 | $102K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,667 | $102K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,698 | $102K |
| 80053 | Comprehensive metabolic panel | <1% | 56,674 | $102K |
| 59025 | Fetal non-stress test | <1% | 4,934 | $101K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,868 | $100K |
| 82330 | <1% | 7,746 | $100K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,434 | $80K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,951 | $78K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,521 | $77K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,482 | $75K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,819 | $73K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 738 | $67K |
| 81025 | <1% | 1,397 | $64K | |
| 86901 | <1% | 4,377 | $64K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,712 | $63K |
| 84702 | <1% | 17,162 | $62K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,040 | $60K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,131 | $59K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 877 | $59K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,654 | $59K |
| 73130 | <1% | 1,420 | $58K | |
| 96376 | <1% | 5,364 | $55K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,804 | $53K |
| 73562 | <1% | 1,902 | $53K | |
| 76801 | <1% | 2,388 | $53K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,338 | $49K |
| 73630 | <1% | 1,825 | $49K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,198 | $49K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,417 | $47K |
| 73030 | <1% | 1,574 | $46K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,823 | $45K |
| 73610 | <1% | 1,794 | $45K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,268 | $42K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,375 | $42K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 585 | $41K |
| 73110 | <1% | 1,202 | $40K | |
| 74018 | <1% | 913 | $39K | |
| 76642 | <1% | 2,233 | $38K | |
| 85652 | <1% | 2,296 | $37K | |
| 82565 | <1% | 1,647 | $37K | |
| 83880 | <1% | 3,884 | $36K | |
| 77065 | Tomosynthesis, mammo | <1% | 635 | $34K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,046 | $34K |
| 93971 | <1% | 2,507 | $34K | |
| 94729 | <1% | 551 | $32K | |
| 78499 | <1% | 789 | $30K | |
| 72100 | <1% | 964 | $29K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,061 | $29K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,032 | $28K |
| 84484 | <1% | 15,764 | $28K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 984 | $28K |
| 87081 | <1% | 1,352 | $28K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,374 | $28K |
| 93325 | <1% | 680 | $28K | |
| 83605 | <1% | 16,731 | $27K | |
| 83690 | <1% | 18,306 | $27K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 8,949 | $27K |
| 70486 | <1% | 905 | $27K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,641 | $25K |
| 97602 | <1% | 411 | $23K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,557 | $22K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,554 | $22K |
| 93017 | <1% | 2,023 | $22K | |
| 86900 | <1% | 3,210 | $21K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 767 | $21K |
| 93970 | <1% | 645 | $20K | |
| 87070 | <1% | 1,902 | $19K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,164 | $19K |
| 73090 | <1% | 399 | $19K | |
| 71250 | <1% | 433 | $18K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,371 | $18K |
| 88307 | <1% | 751 | $18K | |
| 73080 | <1% | 405 | $17K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,215 | $16K |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | <1% | 1,927 | $16K |
| 86850 | <1% | 3,011 | $16K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 806 | $15K |
| 10060 | <1% | 509 | $15K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 477 | $15K |
| 89060 | <1% | 390 | $14K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 928 | $14K |
| 76770 | <1% | 832 | $14K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,970 | $14K |
| 93356 | <1% | 90 | $14K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,390 | $14K |
| 87210 | <1% | 1,947 | $13K | |
| 87631 | <1% | 157 | $13K | |
| 78492 | <1% | 786 | $13K | |
| J3490 | Unclassified drugs | <1% | 554 | $13K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,703 | $13K |
| 80061 | Lipid panel | <1% | 2,090 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,698 | $12K |
| 73590 | <1% | 733 | $12K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,134 | $12K |
| 87205 | <1% | 1,521 | $12K | |
| 93320 | <1% | 380 | $12K | |
| 87186 | <1% | 3,707 | $11K | |
| 88342 | <1% | 856 | $11K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,191 | $11K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,749 | $10K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,573 | $10K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 17 | $10K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 361 | $10K |
| 91200 | <1% | 191 | $10K | |
| 93351 | <1% | 40 | $10K | |
| 97116 | <1% | 593 | $10K | |
| 82803 | <1% | 4,810 | $10K | |
| 84132 | <1% | 1,784 | $9K | |
| 73140 | <1% | 114 | $9K | |
| 82805 | <1% | 385 | $9K | |
| 73502 | <1% | 470 | $9K | |
| 85379 | <1% | 5,217 | $9K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 83 | $8K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,276 | $8K |
| 84703 | <1% | 2,581 | $8K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 217 | $8K |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 302 | $8K |
| 72141 | <1% | 113 | $8K | |
| 12001 | <1% | 432 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,623 | $7K |
| 72131 | <1% | 734 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,224 | $7K |
| 97161 | <1% | 191 | $7K | |
| 83735 | <1% | 7,191 | $7K | |
| 84466 | <1% | 986 | $7K | |
| 72170 | <1% | 280 | $7K | |
| 97162 | <1% | 324 | $6K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,801 | $6K |
| 97597 | <1% | 231 | $6K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 726 | $6K |
| 11045 | <1% | 162 | $6K | |
| 94010 | <1% | 210 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,221 | $5K |
| 87040 | <1% | 3,463 | $5K | |
| 89051 | <1% | 168 | $5K | |
| 78434 | <1% | 1,134 | $5K | |
| 80076 | <1% | 1,238 | $5K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,420 | $5K |
| 86923 | <1% | 526 | $5K | |
| 82947 | <1% | 917 | $5K | |
| 72040 | <1% | 132 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 507 | $4K |
| 10061 | <1% | 179 | $4K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 44 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 143 | $4K |
| 77336 | <1% | 125 | $4K | |
| 80197 | <1% | 2,926 | $4K | |
| 84439 | <1% | 1,870 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 758 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,520 | $4K |
| 84100 | <1% | 2,896 | $4K | |
| 90675 | <1% | 44 | $3K | |
| 87077 | <1% | 1,229 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 213 | $3K |
| 76882 | <1% | 67 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 294 | $3K |
| 96415 | <1% | 253 | $3K | |
| 87088 | <1% | 3,283 | $3K | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 24 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,415 | $2K |
| 96367 | <1% | 764 | $2K | |
| 82728 | <1% | 1,681 | $2K | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 33 | $2K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 976 | $2K |
| 85730 | <1% | 2,956 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 163 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,390 | $2K |
| 81003 | <1% | 201 | $2K | |
| 70498 | <1% | 1,195 | $2K | |
| 94618 | <1% | 32 | $2K | |
| 49083 | <1% | 126 | $2K | |
| 76376 | <1% | 30 | $2K | |
| 87075 | <1% | 565 | $2K | |
| 72128 | <1% | 382 | $2K | |
| 70496 | <1% | 1,248 | $2K | |
| 76536 | <1% | 16 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 324 | $2K |
| 93225 | <1% | 28 | $2K | |
| 90686 | <1% | 402 | $2K | |
| 83516 | <1% | 130 | $2K | |
| 74019 | <1% | 54 | $2K | |
| 83970 | <1% | 162 | $2K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 68 | $2K |
| 83615 | <1% | 1,036 | $1K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 235 | $1K |
| 43235 | <1% | 102 | $1K | |
| 82570 | <1% | 1,329 | $1K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 477 | $1K |
| 12002 | <1% | 178 | $1K | |
| 90715 | <1% | 1,385 | $1K | |
| 77080 | <1% | 13 | $1K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 481 | $1K |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 42 | $1K |
| 86790 | <1% | 283 | $1K | |
| 93975 | <1% | 13 | $1K | |
| 82607 | <1% | 861 | $1K | |
| 82248 | <1% | 60 | $1K | |
| 86140 | <1% | 3,343 | $1K | |
| 84156 | <1% | 272 | $949.95 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 70 | $911.92 |
| 87807 | <1% | 17 | $866.47 | |
| 70544 | <1% | 54 | $829.03 | |
| 87522 | Neg quan hep c or qual rna | <1% | 125 | $807.88 |
| 29125 | <1% | 147 | $803.79 | |
| 80069 | <1% | 391 | $787.37 | |
| 82105 | <1% | 533 | $774.87 | |
| 77062 | <1% | 142 | $734.61 | |
| 93226 | <1% | 66 | $708.19 | |
| 76870 | <1% | 43 | $680.93 | |
| 83540 | <1% | 1,020 | $663.33 | |
| 82550 | <1% | 1,285 | $662.67 | |
| 94644 | <1% | 32 | $611.35 | |
| 93798 | <1% | 35 | $584.38 | |
| 82107 | <1% | 13 | $540.35 | |
| 84520 | <1% | 43 | $539.11 | |
| 74230 | <1% | 17 | $490.97 | |
| 87340 | <1% | 714 | $487.89 | |
| 72158 | <1% | 14 | $353.24 | |
| 88304 | <1% | 721 | $334.34 | |
| 77300 | <1% | 16 | $332.63 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 63 | $296.70 |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 21 | $292.32 |
| 73060 | <1% | 16 | $291.76 | |
| G0378 | Hospital observation service, per hour | <1% | 710 | $283.20 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 154 | $282.68 |
| 89050 | <1% | 128 | $261.56 | |
| 82784 | <1% | 65 | $255.61 | |
| 86803 | <1% | 359 | $232.74 | |
| 12011 | <1% | 69 | $218.88 | |
| 90662 | <1% | 12 | $218.62 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 300 | $192.91 |
| 97130 | <1% | 448 | $155.70 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 129 | $151.17 |
| 86706 | <1% | 473 | $132.12 | |
| 73552 | <1% | 16 | $122.76 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 60 | $86.81 |
| 86780 | <1% | 44 | $79.40 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 62 | $75.11 |
| 97165 | <1% | 28 | $49.84 | |
| 80175 | <1% | 13 | $42.50 | |
| 97166 | <1% | 29 | $40.40 | |
| 82043 | <1% | 304 | $34.88 | |
| 86038 | <1% | 49 | $29.84 | |
| 76937 | <1% | 362 | $28.15 | |
| 80164 | <1% | 17 | $22.94 | |
| G0008 | Administration of influenza virus vaccine | <1% | 121 | $18.69 |
| 96417 | <1% | 271 | $12.61 | |
| 84478 | <1% | 394 | $7.61 | |
| 82010 | <1% | 422 | $5.72 | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 0% | 91 | $0.00 |
| 97129 | 0% | 446 | $0.00 | |
| 85007 | 0% | 115 | $0.00 | |
| 84145 | 0% | 151 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 24 | $0.00 |
| 80074 | 0% | 12 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 75 | $0.00 |
| 88302 | 0% | 48 | $0.00 | |
| 83951 | 0% | 13 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 76 | $0.00 |
| 92610 | 0% | 28 | $0.00 | |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 46 | $0.00 |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 14 | $0.00 |
| 47562 | 0% | 25 | $0.00 | |
| 43249 | 0% | 16 | $0.00 | |
| 82140 | 0% | 30 | $0.00 | |
| 84550 | 0% | 14 | $0.00 | |
| 77061 | 0% | 14 | $0.00 | |
| 88313 | 0% | 21 | $0.00 | |
| 88331 | 0% | 16 | $0.00 | |
| 96368 | 0% | 78 | $0.00 | |
| 36430 | 0% | 216 | $0.00 | |
| 77001 | 0% | 14 | $0.00 | |
| 86704 | 0% | 183 | $0.00 | |
| 88341 | 0% | 120 | $0.00 | |
| 74174 | 0% | 14 | $0.00 | |
| 80178 | 0% | 14 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 63 | $0.00 |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 0% | 16 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 15 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 75 | $0.00 |
| 70491 | 0% | 132 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 45 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 14 | $0.00 |
| 82746 | 0% | 25 | $0.00 | |
| 82945 | 0% | 17 | $0.00 | |
| 87147 | 0% | 16 | $0.00 | |
| 84157 | 0% | 17 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 13 | $0.00 |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, DENIS (CFO)
| Provider | Location | Paid |
|---|---|---|
| Ihc Health Services, INC. | St George, UT | $65.78M |
| Ihc Health Services INC | Ogden, UT | $54.08M |
| Ihc Health Services, INC. | Provo, UT | $44.35M |
| Ihc Health Services INC | Logan, UT | $25.34M |
| Ihc Health Services, INC. | Cedar City, UT | $20.40M |
| Ihc Health Services, INC. | Salt Lake City, UT | $19.91M |
| Ihc Health Services, INC. | American Fork, UT | $17.19M |
| Ihc Health Services INC | Riverton, UT | $15.31M |
| Ihc Health Services INC | Sandy, UT | $11.66M |
| Ihc Health Services, INC. | Layton, UT | $11.61M |
| Ihc Health Services, INC. | Burley, ID | $5.14M |
| Ihc Health Services INC | Murray, UT | $4.64M |
| Ihc Health Services INC | St George, UT | $4.35M |
| Ihc Health Services INC | Heber City, UT | $4.31M |
| Ihc Health Services, INC. | Orem, UT | $4.18M |
| Ihc Health Services, INC. | Richfield, UT | $3.87M |
| Ihc Health Services INC | Tremonton, UT | $3.55M |
| Ihc Health Services, INC. | Spanish Fork, UT | $3.49M |
| Ihc Health Services INC | Park City, UT | $2.53M |
| Ihc Health Services, INC. | Mt Pleasant, UT | $2.34M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.